It is characterized by sustained and substantial reduction of the peripheral lymphocyte counts, mainly CD4-T and CD8-T cells in COVID-19 patients, and is associated with a high risk of developing secondary bacterial infection. This evidence concerns the gene CD8A and COVID-19.